Retour à la carte

Medicines for Malaria Venture

The Swiss Malaria Group members are operating in almost all malaria endemic countries. With their commitment they are contributing to the global fight against malaria. For more information on our members, please go to the member's website by clicking on the member's logo.

Project 1

Making injectable and rectal artesunate available to vulnerable populations to address severe malaria (--> reduction in deaths of young children with severe malaria from 8% to < 0.5%)

Pays

zambia nigeria

Impact

5 districts, 74% of their population (ca. 54,000) 225 Community Health Volunteers Population covered aimed to be scaled up to 268,800

Durée

2010 - ongoing

Activité

Treatment

Project 2

Supporting development of a key easy-to-administer and long-protective antimalarial - dihydroartemisinin-piperaquine (Euroartesim).

Pays

indonesia mozambique tanzania zambia

Durée

Ongoing

Activité

Treatment

Project 3

Moving towards the elimination of P. vivax malaria - tafenoquine.

Pays

brazil ethiopia thailand india peru colombia myanmar vietnam laos cambodia

Durée

5-year roll-out plan for all countries

Activité

Treatment

Project 4

Pyramax, the newest ACT combination approved by a stringent regulatory authority.

Pays

Impact

8,000 (projected), 5,700 until Sept 2018

Durée

3 year CANTAM study

Activité

Treatment

Project 5

Chemoprevention of seasonal P. falciparum malaria in children.

Pays

burkina-faso cameroon chad gambia guinea guinea-bissau ghana mali niger nigeria senegal togo

Impact

29 million children

Activité

Treatment

Project 6

Supporting malaria elimination in Papua New Guinea.

Pays

papua-new-guinea

Impact

21,000 (population living in Lihir) 5,000 cases of malaria in 2015

Durée

2011 - ongoing

Activité

Treatment